See more : New Zealand Coastal Seafoods Limited (NZS.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Pyxis Oncology, Inc. (PYXS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pyxis Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Distribuzione Elettrica Adriatica S.p.a. (DEA.MI) Income Statement Analysis – Financial Results
- China Longyuan Power Group Corporation Limited (CLPXY) Income Statement Analysis – Financial Results
- REMEDIUM LIFECARE LIMITED (REMLIFE.BO) Income Statement Analysis – Financial Results
- Capital Product Partners L.P. (CPLP) Income Statement Analysis – Financial Results
- sinops Inc. (4428.T) Income Statement Analysis – Financial Results
Pyxis Oncology, Inc. (PYXS)
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.00M | 1.84M | 1.25M | 444.00K | 0.00 |
| Gross Profit | -2.00M | -1.84M | -1.25M | -444.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 49.59M | 86.13M | 51.05M | 9.05M | 1.22M |
| General & Administrative | 32.61M | 37.35M | 18.66M | 3.85M | 1.66M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.61M | 37.35M | 18.66M | 3.85M | 1.66M |
| Other Expenses | 0.00 | 0.00 | 181.00K | 0.00 | 0.00 |
| Operating Expenses | 82.20M | 123.48M | 69.72M | 12.89M | 2.88M |
| Cost & Expenses | 82.20M | 123.48M | 69.72M | 12.89M | 2.88M |
| Interest Income | 6.63M | 2.76M | 23.00K | 66.00K | 107.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.00M | 1.84M | 1.25M | 444.00K | 2.88M |
| EBITDA | -78.49M | -122.77M | -69.07M | -12.43M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -82.20M | -123.48M | -69.72M | -12.89M | -2.88M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.41M | 2.76M | -6.26M | 66.00K | 107.00K |
| Income Before Tax | -73.79M | -120.72M | -75.98M | -12.83M | -2.77M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.76M | 5.56M | -66.00K | -107.00K |
| Net Income | -73.79M | -117.95M | -81.54M | -12.76M | -2.67M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.85 | -3.57 | -2.53 | -0.37 | -0.08 |
| EPS Diluted | -1.85 | -3.57 | -2.53 | -0.37 | -0.08 |
| Weighted Avg Shares Out | 39.90M | 33.03M | 32.22M | 34.31M | 34.31M |
| Weighted Avg Shares Out (Dil) | 39.90M | 33.03M | 32.22M | 34.31M | 34.31M |
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ: PYXS)
Source: https://incomestatements.info
Category: Stock Reports